AngioDynamics Inc. (ANGO) — Q2 2026 results
AngioDynamics reported quarterly revenue of $79.4 million, up 9.0% year-over-year and above the consensus revenue estimate of $77.8 million. Gross profit rose to $44.8 million, a 12.2% increase versus the prior year. Despite revenue strength, the company recorded an operating loss of $6.1 million (down 44.8% year-over-year) and a net loss attributable to common shareholders of $6.4 million (down 40.9% year-over-year). Diluted loss per share came in at $0.15, compared with an estimated loss per share of $0.10.
Cash flow and balance sheet highlights show improved operating cash generation and a reduction in liabilities. Cash from operating activities increased to $4.7 million (up 88.5% year-over-year), while purchases of property, plant and equipment totaled $1.6 million (down 17.3% year-over-year). The company held $41.6 million in cash and cash equivalents (down 23.0% YoY) and reported total liabilities of $93.3 million (down 10.9% YoY).
Overall, AngioDynamics (ANGO) delivered revenue above expectations and materially improved operating cash flow, but remains unprofitable at both the operating and net levels this quarter. Cost of sales increased modestly to $34.7 million, helping support the gross profit expansion even as operating expenses pressure profitability.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
AngioDynamics Inc. Insider Trading Activity
AngioDynamics Inc. insiders have traded $ANGO stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ANGO stock by insiders over the last 6 months:
- LAWRENCE T WEISS (SVP, Chief Legal Officer) purchased 10,000 shares for an estimated $118,100
- JAMES C CLEMMER (President and CEO) purchased 10,000 shares for an estimated $111,500
- STEPHEN A TROWBRIDGE (EVP and CFO) purchased 890 shares for an estimated $9,932
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AngioDynamics Inc. Hedge Fund Activity
We have seen 76 institutional investors add shares of AngioDynamics Inc. stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 609,906 shares (+31.3%) to their portfolio in Q3 2025, for an estimated $6,812,650
- UBS GROUP AG added 501,881 shares (+83.6%) to their portfolio in Q3 2025, for an estimated $5,606,010
- AIGH CAPITAL MANAGEMENT LLC removed 474,488 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,300,030
- MILLENNIUM MANAGEMENT LLC added 393,682 shares (+28.1%) to their portfolio in Q3 2025, for an estimated $4,397,427
- BASTION ASSET MANAGEMENT INC. added 304,960 shares (+31.8%) to their portfolio in Q3 2025, for an estimated $3,406,403
- DIVISADERO STREET CAPITAL MANAGEMENT, LP added 282,695 shares (+8.3%) to their portfolio in Q3 2025, for an estimated $3,157,703
- PHOCAS FINANCIAL CORP. added 269,416 shares (+79.6%) to their portfolio in Q3 2025, for an estimated $3,009,376
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AngioDynamics Inc. Government Contracts
We have seen $75,000 of award payments to $ANGO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TISSUE ABLATION SYSTEM: $75,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AngioDynamics Inc. Congressional Stock Trading
Members of Congress have traded $ANGO stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ANGO stock by members of Congress over the last 6 months:
- REPRESENTATIVE DEBBIE WASSERMAN SCHULTZ has traded it 2 times. They made 0 purchases and 2 sales worth up to $15,000 on 10/20, 07/16.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AngioDynamics Inc. Analyst Ratings
Wall Street analysts have issued reports on $ANGO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/16/2025
- Lake Street issued a "Buy" rating on 07/16/2025
To track analyst ratings and price targets for AngioDynamics Inc., check out Quiver Quantitative's $ANGO forecast page.
AngioDynamics Inc. Price Targets
Multiple analysts have issued price targets for $ANGO recently. We have seen 3 analysts offer price targets for $ANGO in the last 6 months, with a median target of $18.0.
Here are some recent targets:
- William Plovanic from Canaccord Genuity set a target price of $18.0 on 10/03/2025
- Yi Chen from HC Wainwright & Co. set a target price of $16.0 on 07/16/2025
- Frank Takkinen from Lake Street set a target price of $24.0 on 07/16/2025
